Price · as of 2025-12-31
$33.38
Market cap 4.97B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $55.71 | +66.9% |
| Intrinsic Value(DCF) | $15.38 | -53.92% |
| Graham-Dodd Method(GD) | $17.87 | -46.46% |
| Graham Formula(GF) | $4.63 | -86.13% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $17.24 | $41.19 | $17.42 | $2.01 | $0.00 |
| 2012 | $15.39 | $39.19 | $71.05 | $6.73 | $10.18 |
| 2013 | $31.05 | $592.86 | $78.43 | $7.47 | $1.54 |
| 2014 | $66.39 | $52.83 | $2.39 | $7.93 | $0.00 |
| 2015 | $32.91 | $54.13 | $2.81 | $0.57 | $0.00 |
| 2016 | $57.22 | $44.40 | $1.33 | $0.49 | $0.00 |
| 2017 | $58.49 | $51.05 | $32.31 | $2.09 | $0.00 |
| 2018 | $31.93 | $35.65 | $86.25 | $2.46 | $0.00 |
| 2019 | $18.99 | $31.79 | $0.67 | $0.06 | $0.00 |
| 2020 | $19.42 | $32.57 | $1.72 | $2.64 | $1.80 |
| 2021 | $24.38 | $36.74 | $1.95 | $4.84 | $0.00 |
| 2022 | $26.61 | $36.84 | $1.82 | $1.03 | $0.00 |
| 2023 | $29.25 | $68.02 | $164.18 | $17.44 | $118.94 |
| 2024 | $34.35 | $60.15 | $82.55 | $19.45 | $4.46 |
| 2025 | $30.25 | $55.71 | $9.52 | $17.87 | $4.63 |
AI valuation
Our deep-learning model estimates Alkermes plc's (ALKS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $55.71
- Current price
- $33.38
- AI upside
- +66.9%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$15.38
-53.92% upside
Graham-Dodd
$17.87
-46.46% upside
Graham Formula
$4.63
-86.13% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ALKS | Alkermes plc | $33.38 | 4.97B | +67% | -54% | -46% | -86% | 20.62 | 2.74 | 3.38 | 13.49 | — | 2.87 | 86.31% | 17.21% | 16.37% | 14.72% | 20.15% | 10.64% | 0.04 | 20.69 | 2.06 | 1.70 | -1.57 | -3410.00% | -525.00% | -9987.00% | 0.01% | 0.00 | 0.05% | 0.00% | 0.00% | 6.08% | 17.58 | 8571.26 | 3.02 | 5.27 |
| ACAD | ACADIA Pharmaceuticals In… | $24.56 | 4.16B | +74% | +42% | -54% | +114% | 12.85 | 3.97 | 3.04 | 22.02 | — | 4.75 | 91.46% | 24.10% | 23.64% | 38.89% | 513.41% | 23.39% | 0.07 | — | 2.38 | 2.18 | -2.67 | -46757.00% | 3185.00% | -77327.00% | 5.40% | 0.40 | 398.52% | 0.00% | 0.00% | 4.68% | 9.56 | 14.03 | 2.30 | 3.24 |
| ACLX | Arcellx, Inc. | $113.79 | 6.58B | -42% | — | — | — | -28.05 | — | — | -31.38 | -27.10 | — | 0.00% | — | — | -100.68% | 644.58% | -39.69% | — | -10.45 | — | — | 0.00 | 10350.00% | -10000.00% | 11938.00% | -3.31% | — | 541.60% | 0.00% | 0.00% | 0.02% | -25.37 | -30.21 | — | — |
| AKRO | Akero Therapeutics, Inc. | $54.65 | 4.5B | — | — | — | — | -11.22 | 3.77 | — | -7.43 | -37.70 | 3.77 | 0.00% | — | — | -39.22% | -1042.60% | -35.85% | 0.05 | -61.14 | 19.38 | 18.69 | 1.06 | 2976.00% | — | 5898.00% | -8.17% | -5.79 | -844.19% | 0.00% | 0.00% | 3.41% | -7.43 | -9.18 | — | 20.91 |
| ARWR | Arrowhead Pharmaceuticals… | $63.27 | 8.86B | +5,558% | +96,147% | -95% | — | 272.90 | 17.63 | 9.91 | 46.50 | — | 17.90 | 97.12% | 11.86% | -0.20% | 9.24% | 42.67% | 2.39% | 0.79 | 1.10 | 4.86 | 4.74 | 0.85 | -9976.00% | 2325815.00% | -12596.00% | 1.91% | 0.92 | 116.49% | 0.00% | 0.00% | 7.42% | 77.94 | 48.86 | 9.24 | 5.43 |
| CRSP | CRISPR Therapeutics AG | $60.14 | 5.77B | -40% | -46% | — | +738% | -9.40 | 2.84 | 1556.91 | -7.08 | -19.15 | 2.84 | -6537.01% | -16191.40% | -16569.77% | -30.18% | -191.73% | -25.81% | 0.21 | — | 13.32 | 13.25 | -0.07 | 4908.00% | -8997.00% | 13911.00% | -6.33% | -2.31 | -116.70% | 0.00% | 0.00% | 0.00% | -6.83 | -11.23 | 1106.51 | 8.49 |
| KYMR | Kymera Therapeutics, Inc. | $91.35 | 7.31B | -43% | -53% | -100% | -68% | -24.42 | 4.81 | 193.97 | -22.56 | -102.50 | 4.81 | 100.00% | -891.33% | -794.39% | -25.78% | -55.98% | -22.89% | 0.05 | -1403.21 | 10.47 | 10.19 | 0.91 | 2383.00% | -1672.00% | 1302.00% | -3.08% | -2.80 | -37.55% | 0.00% | 0.00% | 3.19% | -19.57 | -29.18 | 174.43 | 27.01 |
| PCVX | Vaxcyte, Inc. | $61.74 | 8.86B | — | — | — | — | -11.00 | 3.14 | — | -9.58 | -22.85 | 3.14 | 0.00% | — | — | -25.59% | -61.93% | -23.38% | 0.09 | — | 7.91 | 7.81 | -0.07 | 4816.00% | — | 4089.00% | -7.93% | -3.19 | -44.87% | 0.00% | 0.00% | 0.00% | -7.69 | -10.61 | — | 12.61 |
| PTCT | PTC Therapeutics, Inc. | $68.19 | 5.47B | +340% | +35% | -42% | +1,382% | 7.73 | -25.71 | 3.05 | 4.31 | — | -7.80 | 95.85% | 49.49% | 39.44% | -104.75% | -117.79% | 29.58% | -2.40 | 5.63 | 2.35 | 2.20 | -0.55 | -26448.00% | 11451.00% | -48603.00% | 13.31% | 0.73 | -98.57% | 0.00% | 0.00% | 41.37% | 4.47 | 5.45 | 2.21 | 1.69 |
| PTGX | Protagonist Therapeutics,… | $92.08 | 5.76B | -20% | -55% | — | +72% | — | 9.75 | 130.20 | -42.43 | — | 9.75 | 97.34% | -343.63% | -282.83% | 0.00% | -97.33% | 0.00% | 0.02 | — | 12.71 | 12.49 | 0.92 | -14846.00% | -8941.00% | -6932.00% | 0.94% | 1.27 | 34.52% | 0.00% | — | 0.53% | -34.37 | 96.90 | 118.09 | 66.47 |
| TGTX | TG Therapeutics, Inc. | $30.09 | 4.78B | +200% | +4,085% | -34% | +845% | 9.49 | 6.55 | 6.88 | 33.25 | 0.54 | 6.55 | 83.62% | 20.01% | 72.56% | 102.75% | 36.31% | 54.50% | 0.01 | 4.61 | 4.10 | 2.91 | -0.58 | 174667.00% | 8732.00% | -3840.00% | -0.59% | -0.16 | -7.36% | 0.00% | 0.00% | 5.57% | 33.32 | -164.45 | 6.67 | 6.21 |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
- CEO
- Richard F. Pops
- Employees
- 1.8K
- Beta
- 0.46
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($15.38 ÷ $33.38) − 1 = -53.92% (DCF, example).